The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD

PHASE4RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 2, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

May 31, 2027

Conditions
Neuropathic PainPTSD
Interventions
DRUG

Ketamine

Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr. Participants will receive intravenous infusions of ketamine for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (ketamine 0.5 mg/kg IBW/hr)

DRUG

Magnesium sulfate

Magnesium sulfate 3 grams will be diluted into 250 mL normal saline and infused at a rate of 62.5 mL/hr (over 4 hours until the entire contents are infused and then flushed with 20 mL of normal saline). The Mg only group will be randomly assigned to one of the treatment groups (moderate dose ketamine, or moderate dose ketamine +Mg) after 2 weeks and complete the full 24-week infusion treatment regime of the randomly selected treatment group in an outpatient setting.

DRUG

Ketamine + Magnesium sulfate

Participants will receive intravenous infusions of ketamine and magnesium sulfate in combination. Ketamine will be placed in 250 mL normal saline and infused at a rate of 62.5 mL/hr Participants will receive intravenous infusions of ketamine and magnesium sulfate for 4 hours each day in diminishing number of dosing events per week for the full 24-week infusion regime in an outpatient setting. (Ketamine 0.5 mg/kg IBW/hr + magnesium sulfate 3 grams diluted into 250 mL normal saline)

Trial Locations (1)

78234

RECRUITING

Brooke Army Medical Center, San Antonio

All Listed Sponsors
lead

Margaux M. Salas, PhD

FED

NCT06414356 - The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD | Biotech Hunter | Biotech Hunter